Are you aware that a mother's asthma can impact her baby's lung health even before birth? Groundbreaking research reveals a fascinating link between maternal asthma management and infant lung development. This study delves into how a common asthma treatment might offer a crucial shield for newborns.
Mothers with asthma face unique challenges, and their babies can be more susceptible to early lung function issues. These challenges could potentially lead to respiratory problems later in life. Inhaled corticosteroids (ICS) are a widely used treatment for asthma during pregnancy. However, the impact of these medications on the developing lungs of the unborn child has been a subject of ongoing investigation. This study sought to clarify whether the use of ICS during pregnancy could counteract the potential negative effects of maternal asthma on the baby's lung health.
So, how did they find this out? The researchers examined 186 infants, carefully assessing their lung function between 4-6 weeks of age. They used advanced techniques, like tidal breathing flow-volume loops and functional residual capacity (FRC), to measure lung function. The study compared the outcomes of infants whose mothers used ICS during pregnancy with those whose mothers did not, as well as with infants born to mothers without asthma. The key measurement was the tPTEF:tE ratio, adjusted for FRC, which is a sensitive indicator of early airway function.
The results are quite compelling. Infants born to asthmatic mothers who were exposed to ICS in the womb showed a significant improvement in the tPTEF:tE ratio compared to those whose mothers did not use ICS (coefficient of 0.06/mL, with a 95% confidence interval of 0.01–0.11, and a p-value of 0.014). But here's where it gets interesting: infants of asthmatic mothers not using ICS had lower tPTEF:tE ratios compared to the control group (coefficient of -0.08/mL, with a 95% confidence interval of -0.01 to -0.02, and a p-value of 0.012). In contrast, infants exposed to ICS showed no significant difference from the control group (coefficient of -0.02/mL, with a 95% confidence interval of -0.06 to 0.03, and a p-value of 0.453). This suggests that ICS use during pregnancy might actually reverse the early lung function deficits associated with maternal asthma.
This study suggests that inhaled corticosteroids could be a valuable tool to protect infant lung development when asthma complicates pregnancy. Future research will be crucial to understand the long-term respiratory health of these children.
What do you think? Does this change your perspective on asthma management during pregnancy? Share your thoughts in the comments!
Reference: Martins Costa Gomes G et al. Association between maternal asthma and impaired infant lung function is diminished by inhaled corticosteroid use in pregnancy. Thorax. 2025; DOI:10.1136/thorax-2025-223539.
This article is available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.
